Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report)'s share price gapped down before the market opened on Friday . The stock had previously closed at $32.66, but opened at $22.39. Monopar Therapeutics shares last traded at $21.56, with a volume of 2,178,985 shares trading hands.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on MNPR. HC Wainwright lifted their price objective on Monopar Therapeutics from $2.00 to $6.00 and gave the company a "buy" rating in a research note on Wednesday, August 14th. Rodman & Renshaw assumed coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They issued a "buy" rating and a $50.00 price target on the stock.
Get Our Latest Report on MNPR
Monopar Therapeutics Stock Performance
The company has a 50-day moving average price of $4.58 and a 200-day moving average price of $3.83. The firm has a market capitalization of $296.00 million, a price-to-earnings ratio of -38.50 and a beta of 1.26.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its earnings results on Friday, August 9th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). On average, research analysts expect that Monopar Therapeutics Inc. will post -1.93 earnings per share for the current fiscal year.
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Recommended Stories
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
